weight loss, NHS in Scotland
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Who can get weight loss drugs on the NHS in Scotland?
The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
A nutritionist who lost 100 pounds using a diet he designed himself claims apples "do the exact same thing" as weight-loss ...
Recent studies have shown an association between drugs such as Ozempic, Mounjaro and Wegovy — which have become phenomenally popular for weight loss — and an increased risk of NAION.
Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to ...
Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and ...
Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type-2 diabetes. However, when the drugs are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback